Trial · NCT03591731
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
NCT03591731, Phase 2, Completed, Intergroupe Francophone de Cancerologie Thoracique
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs). Trials, record NCT03591731. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03591731
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
- NCT number
- NCT03591731
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 185 participants, actual
- Lead sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Conditions
- Neuroendocrine Carcinoma
- Interventions
- Nivolumab, Ipilimumab
- First posted
- 2018-07-19
- Last updated
- 2025-04-01
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate | 8 weeks after randomization | Number of patients with a best overall response of complete response (CR) or partial response (PR) assessed by investigators using validated criteria (i.e. RECIST 1.1) divided by the number of eligible patients. |
| Secondary | Objective response rate assessed by independent central review | 8 weeks after randomization | Number of patients with a best overall response of complete response (CR) or partial response (PR) assessed by independent central review using validated criteria (i.e. RECIST 1.1) divided by the number of eligible patients. |
| Secondary | Disease control rate assessed by independent central review | 8 weeks after randomization | Percentage of patients who will achieve complete response, partial response or stable disease |
| Secondary | Response duration | 24 months after randomization of the last subject | Time between the date of the best overall response of partial or complete response until the date of progressive disease or death due to any cause. |
| Secondary | Time to symptom deterioration | 24 months after randomization of the last subject | Time between the date of treatment start and the date of event defined as the first documented symptom deterioration |
| Secondary | Progression-free survival | 24 months after randomization of the last subject | Time between the date of treatment start and the date of event defined as the first documented disease progression or death from any cause. |
| Secondary | Overall Survival | 24 months after randomization of the last subject | Time between the date of treatment start and the date of death from any cause. |
| Secondary | Frequency of adverse events | 24 months after randomization of the last subject |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41774886 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03591731
GET https://conductscience.org/api/trials/v1/NCT03591731/registered